Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme

PHASE I CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROMEFIRST DOSING OF FIRST STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 2 M TO EVOTECHAMBURG, GERMANY / ACCESSWIRE / June 29, 2023 / Evotec SE …